• About

  • Services

  • Contact

  • Blog

  • More

    Use tab to navigate through the menu items.
    Recent Posts
    • LinkedIn Social Icon
    Planning for a New Era: Commercial Strategy under the Lens of Public Scrutiny

    Planning for a New Era: Commercial Strategy under the Lens of Public Scrutiny

    In 2019, 44% of novel drugs approved in the U.S were classified with orphan designation. 60% of approved drugs fell into one or more expedited categories: Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval. But how does public concern over increasingly high drug prices impact patients in need of newly available, life-altering medications? Does the political environment and legislation influence your business strategy? Clinical stage companies must begin de

    What is the impact of rare diseases on individuals and health care systems?

    Congressionally funded report details diagnostic challenges  and costs of rare diseases in the US

    Congressionally funded report details diagnostic challenges and costs of rare diseases in the US

    Diagnostics: Moving to the forefront of Global Healthcare

    Diagnostics: Moving to the forefront of Global Healthcare

    Economic Burden of Rare Diseases Nearly $1 Trillion

    Economic Burden of Rare Diseases Nearly $1 Trillion

    CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs

    CBO Comparison of Brand-Name Drug Prices Among Selected Federal Programs

    Orphan drugs account for more than half of all FDA drug approvals in 2020

    Orphan drugs account for more than half of all FDA drug approvals in 2020

    Rare Disease Stakeholders: Do mRNA COV19 Vaccines Affect Eligibility to Receive Future Gene Therapy?

    Rare Disease Stakeholders: Do mRNA COV19 Vaccines Affect Eligibility to Receive Future Gene Therapy?

    How do we identify and measure value for patients with rare diseases?

    How do we identify and measure value for patients with rare diseases?

    National Burden of Rare Disease Survey

    HVH Precision Analytics and Diligentia Strategy Announce Upcoming Presentation at the 2020 American

    HVH Precision Analytics and Diligentia Strategy Announce Upcoming Presentation at the 2020 American

    © 2021 Diligentia LLC

    Back to top

    (202) 744-0755